



NATIONAL ASSOCIATION OF NUCLEAR PHARMACIES

Position Statement

Appropriate Compounding

The National Association of Nuclear Pharmacies (NANP) supports appropriate pharmacist compounding of pharmaceutical and radiopharmaceutical preparations for use in nuclear medicine.

- Compounding differs from the routine preparation and dispensing of FDA approved products in that compounding involves the use of one or more components that are not FDA-approved “finished pharmaceuticals”.
- Adherence to good pharmacy practice, including verification of strength, identity, quality, and purity of all components of the final compounded preparation is necessary to assure a safe and effective product.
- Pharmacists may compound products that are not otherwise commercially available pursuant to a physician’s prescription or compound preparations similar to commercially available products when there is a legitimate medical need.
- We recognize the legitimate need to compound a modified version of a commercially available pharmaceutical or radiopharmaceutical for individual patient concerns is extremely rare.
- In cases of supplier outages of commercially available pharmaceuticals or radiopharmaceuticals, short term compounding of such preparations is appropriate and supported by NANP when physicians prescribe for and patients agree to receive the compounded preparation.

NANP DOES NOT SUPPORT:

- Making copies of commercially available pharmaceuticals, including radiopharmaceuticals, a practice which has been deemed illegal by FDA.
- Claims that by using the same supplier of raw materials as a licensed FDA manufacturer, one produces an FDA-approved product.
- Making small, clinically insignificant changes to a preparation that is otherwise a copy of a commercially available product, in order to claim uniqueness.
- The use of non-FDA-approved ingredients when FDA-approved ingredients are available.

OFFICERS

Executive Director and Chairman
Jeff Norenberg
University of New Mexico

Secretary/Treasurer
Jerry Costanzo
Cardinal Health NPS

Legal Counsel
Chris Ondeck
Crowell & Moring

BOARD OF DIRECTORS

Jerry Costanzo
Cardinal Health NPS

Rich DeVeau
GE Healthcare

Rich Nickel
Covidien

Michael Mosley
PETNet Solutions

Kirk McCall
IBA Molecular

Danny R. Allen
*Independent -
NuTech*

Timothy M. Quinton
*Independent -
Radiopharmacy Inc*

James Ponto
*Institutional/Academic -
University of Iowa*

Perry Polsinelli
United Pharmacy Partners, LLC

Approved November 3, 2009